CoChat

eRapa Restores a Normal Life Span in a FAP Mouse Model

Open access
Hasty, Paul, Livi, Carolina B., Dodds, Sherry G., Jones, Diane, Strong, Randy, Javors, Martin, Fischer, Kathleen E., Sloane, Lauren, Murthy, Kruthi, Hubbard, Gene, Sun, Lishi, Hurez, Vincent, Curiel, Tyler J., Sharp, Zelton Dave · 2014 · Cancer Prevention Research
Cited by 68

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Mutation of a single copy of the adenomatous polyposis coli (APC) gene results in familial adenomatous polyposis (FAP), which confers an extremely high risk for colon cancer. ApcMin/+ mice exhibit multiple intestinal neoplasia (MIN) that causes anemia and death from bleeding by 6 months. Mechanistic target of rapamycin complex 1 (mTORC1) inhibitors were shown to improve ApcMin/+ mouse survival when administered by oral gavage or added directly to the chow, but these mice still died from neoplasia well short of a natural life span. The National Institute of Aging Intervention Testing Program showed that enterically targeted rapamycin (eRapa) extended life span for wild-type genetically heterogeneous mice in part by inhibiting age-associated cancer. We hypothesized that eRapa would be effective in preventing neoplasia and extend survival of ApcMin/+ mice. We show that eRapa improved survival of ApcMin/+ mice in a dose-dependent manner. Remarkably, and in contrast to previous reports, most of the ApcMin/+ mice fed 42 parts per million eRapa lived beyond the median life span reported for wild-type syngeneic mice. Furthermore, chronic eRapa did not cause detrimental immune effects in mouse models of cancer, infection, or autoimmunity, thus assuaging concerns that chronic rapamycin treatment suppresses immunity. Our studies suggest that a novel formulation (enteric targeting) of a well-known and widely used drug (rapamycin) can dramatically improve its efficacy in targeted settings. eRapa or other mTORC1 inhibitors could serve as effective cancer preventatives for people with FAP without suppressing the immune system, thus reducing the dependency on surgery as standard therapy. Cancer Prev Res; 7(1); 169–78. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1940-6207.capr-13-0299

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 68

Metadata

Authors
Hasty, P., Livi, C. B., Dodds, S. G., Jones, D., Strong, R., Javors, M., Fischer, K. E., Sloane, L., Murthy, K., Hubbard, G., Sun, L., Hurez, V., Curiel, T. J., & Sharp, Z. D.
Venue
Cancer Prevention Research
Published
2014-01-01
Volume
7
Issue
1
Pages
169-178
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
OpenAlex
W2126451960
Cited by
68
References
11
FWCI
2.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: eRapa Restores a Normal Life Span in a FAP Mouse Model. https://app.cochat.ai/papers/10.1158/1940-6207.capr-13-0299
The paper
Hasty, P., Livi, C. B., Dodds, S. G., Jones, D., Strong, R., Javors, M., Fischer, K. E., Sloane, L., Murthy, K., Hubbard, G., Sun, L., Hurez, V., Curiel, T. J., & Sharp, Z. D. (2014). eRapa Restores a Normal Life Span in a FAP Mouse Model. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-13-0299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.